Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Docetaxel in Advanced Non-squamous NSCLC
NCT03750916Phase 2Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03750916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750916.